ClinicalTrialsFinder
RecruitingPhase 2NCT04530383

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

An Open Label Clinical Trial of Metformin in Those With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

Sponsor

University of Kansas Medical Center

Enrollment

30 participants

Start Date

Feb 14, 2022

Study Type

INTERVENTIONAL

Conditions

Cystic FibrosisCystic Fibrosis-related Diabetes

Summary

The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Metformin Hydrochloride for people with cystic fibrosis and cystic fibrosis-related diabetes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin Hydrochloride

1000 mg twice daily

Locations(1)

University of Kansas Medical Center

Kansas City, Kansas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04530383

Related Trials

Role of Genetic Factors in the Development of Lung Disease

NCT000015322 locations

FEED-Cystic Fibrosis (FEED-CF)

NCT057667741 location

Natural History of Noncirrhotic Portal Hypertension

NCT024177401 location

Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)

NCT071020431 location

Rare CFTR Mutation Cell Collection Protocol (RARE)

NCT031618081 location